What's Hot
View all perspectives
Dr. John Cush RheumNow
2 years 5 months ago
Watch: New 2022 EULAR RA Treatment Guidelines
https://t.co/mF4cKJLtbr
#EULAR2022 https://t.co/oI8p6gL0Tf
Richard Conway RichardPAConway
2 years 5 months ago
Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU
Richard Conway RichardPAConway
2 years 5 months ago
Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA
Dr. Antoni Chan synovialjoints
2 years 5 months ago
Roberto Giacomeilli from Italy explaining the mechanisms on how COVID-19 may cause rheumatic disease #EULAR2022 @RheumNow https://t.co/a2kTT7vcRx
Richard Conway RichardPAConway
2 years 5 months ago
Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk
@RheumNow
#EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
Dr. Antoni Chan synovialjoints
2 years 5 months ago
Catching up with Jack, a great teacher and educator @RheumNow #rheum #rheumedu #EULAR2022 https://t.co/2wqbhpIb2P
Dr. Rachel Tate uptoTate
2 years 5 months ago
LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, enthesitis, dactylitis, BMI>30 & sDMARDs tx constitutes negative predictive impact on MDA/LDA after 1 yr. #EULAR2022 POS0080 @RheumNow https://t.co/PugwiuSMPm https://t.co/nqadEjA3Xe
Robert B Chao, MD doctorRBC
2 years 5 months ago
Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients
Fast onset, met ACR50 primary endpoint
AE included site reaction and candida infection
@RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl
David Liew drdavidliew
2 years 5 months ago
I could listen to Dennis McGonagle talk about enthesitis all day.
If you missed it, one to check out later #EULAR2022 @RheumNow https://t.co/8pRKqMB06j
Dr. Rachel Tate uptoTate
2 years 5 months ago
Add on MTX does not impair UST immunogenicity in PsA. #EULAR2022 POS0079 @RheumNow
https://t.co/CalEn7KpsX https://t.co/NZUqdX0XKo
Robert B Chao, MD doctorRBC
2 years 5 months ago
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores.
Synovial hypertrophy most responsive.
Hands and feet, wrist and knees most affected and responsive.
@RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa
Dr. Rachel Tate uptoTate
2 years 5 months ago
Novel composite DAPSA LDA +IGA < or = to 1 may be a reliable predictor in long-term PsA skin/joint response (and easier to get than PASDAS in clinic.) @AlexisOgdie #EULAR2022 POS0082 @RheumNow https://t.co/dmMjGcsIcm https://t.co/BHRlGenCyl
David Liew drdavidliew
2 years 5 months ago
Style guide: welcome to the modern era of #EULAR2022
(and here I am, stuck-in-the-mud still wearing my collared shirt/blue blazer)
@RheumNow https://t.co/MXXHWF7Q47
Richard Conway RichardPAConway
2 years 5 months ago
More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0.26) with no evidence of adrenal insufficiency. Can successfully withdraw long term steroids! @RheumNow #EULAR2022 OP0270 https://t.co/IV9iJLY22v https://t.co/ZXdwxlXorK
Poster Hall